Careprost is a topical ophthalmic solution containing the active pharmaceutical ingredient bimatoprost, a prostaglandin analogue originally developed for the management of glaucoma. Its secondary, yet highly sought-after, effect of promoting eyelash growth led to its development and FDA approval as a treatment for hypotrichosis of the eyelashes. This prescription-only treatment works by extending the anagen (growth) phase of the eyelash hair cycle, increasing the percentage of hairs in this active phase, and stimulating the development of thicker, darker, and longer lashes. It represents a significant advancement in dermatological and aesthetic medicine, offering a scientifically-backed solution for individuals with inadequate or not enough eyelashes.

Features

• Active Ingredient: Bimatoprost 0.03% (0.3 mg/mL)
• Formulation: Sterile, isotonic, buffered ophthalmic solution
• Presentation: 3 mL translucent plastic bottle with a sealed, sterile applicator
• Pharmacological Class: Prostaglandin agonist
• Prescription Status: Rx-only medication
• Mechanism: Prostaglandin FP receptor agonist

Benefits

• Achieves measurably longer eyelashes by prolonging the active growth phase of the hair follicle.
• Promotes significantly fuller-looking lashes by increasing the number of hairs growing at any one time.
• Results in visibly darker eyelashes through a proposed mechanism of increased melanogenesis within the hair follicle.
• Provides a clinically validated, non-invasive alternative to cosmetic extensions or tinting.
• Delivers noticeable results typically observed within 4-8 weeks, with full growth achieved after approximately 12-16 weeks of nightly application.
• Effects are maintained with continued use but are reversible upon cessation of treatment, returning lashes to their pre-treatment state.

Common use

Careprost is indicated for the treatment of hypotrichosis (inadequate or not enough eyelashes) by increasing their growth, including length, thickness, and darkness. It is prescribed for adult patients seeking to enhance the aesthetic appearance of their natural eyelashes. Its use is strictly topical and applied to the skin of the upper eyelid margin at the base of the eyelashes. It is not intended for application in the eye, on the lower eyelid, or by individuals under 18 years of age.

Dosage and direction

The recommended dosage is one application per day, administered in the evening. Prior to application, ensure the face is clean, makeup is removed, and contact lenses are taken out (they may be reinserted 15 minutes after application).

1. Remove one sterile applicator from its tray.
2. Holding the sterile applicator horizontally, place one drop of Careprost solution onto the applicator’s area nearest the tip.
3. Immediately draw the applicator carefully across the skin of the upper eyelid margin at the base of the eyelashes, starting from the inner part to the outer part of the eyelid. Do not apply to the lower eyelid.
4. Blot any excess solution beyond the eyelid margin with a tissue.
5. Dispose of the applicator after a single use. Use a new sterile applicator for the other eye to prevent potential cross-contamination.
6. Do not allow the tip of the bottle to contact surrounding structures, fingers, or any other surface, as this may contaminate the solution.

Precautions

• This medication is for external use only. If the solution enters the eye, it is not expected to cause harm. Do not rinse the eye.
• Strictly use one applicator per eye to avoid transferring contaminants from one eyelid to the other.
• Patients should be advised that bimatoprost has been known to cause permanent darkening of the eyelid skin and iris (the colored part of the eye), which may be irreversible. Iris pigmentation changes occur slowly and may not be noticeable for months to years.
• There is a potential for hair growth to occur in other areas of the skin that the solution frequently touches. Any excess solution outside the upper eyelid margin should be blotted away promptly.
• Patients with intraocular inflammation (e.g., uveitis) or those scheduled for eye surgery should use with caution and under close physician supervision.
• The bottle should be discarded 28 days after first opening to prevent microbial contamination and degradation of the solution.

Contraindications

Careprost is contraindicated in patients with:

• Known hypersensitivity to bimatoprost or any other ingredients in the formulation.
• Active or suspected ocular or periocular infections, including conjunctivitis and blepharitis.
• A history of or current herpes simplex keratitis.

Possible side effect

The most frequently reported side effects are generally ocular and localized to the application site. These include:

• Common (≥1-10%): Eye pruritus (itching), conjunctival hyperemia (redness), skin hyperpigmentation of the eyelid, ocular dryness, and eyelash growth (desired effect).
• Less Common (≤1%): Eye irritation, foreign body sensation, blepharitis, cataract, superficial punctate keratitis, eyelid edema (swelling), allergic conjunctivitis, asthenopia (eye strain), increased iris pigmentation, photophobia, and visual disturbances.
• Rare: Periorbital tissue atrophy (hollowing), macular edema, uveitis, and iritis, primarily in patients with pre-existing risk factors.

Drug interaction

Formal drug interaction studies have not been conducted with topical ocular bimatoprost. However, the concomitant use of multiple topical ophthalmic agents may increase the risk of local side effects. It is recommended to administer other eye medications at least 5 minutes apart from Careprost application. There are no known systemic interactions due to low systemic absorption.

Missed dose

If a dose is missed, it should be skipped. The patient should not apply a double dose the next day to make up for the missed application. Resume the usual dosing schedule with the next evening’s application.

Overdose

Topical overdose of Careprost is unlikely to produce life-threatening symptoms. Accidental oral ingestion may lead to systemic prostaglandin-type effects such as headache, nausea, vomiting, and dizziness. In case of accidental ingestion, symptomatic and supportive care is recommended. Topical overdose on the eye or skin may exacerbate known local side effects, such as severe eye irritation, conjunctival hyperemia, or periocular skin darkening. The eyes should be rinsed with warm water if significant irritation occurs.

Storage

• Store unopened bottles in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Once opened, the bottle may be stored at room temperature up to 25°C (77°F) for up to 28 days.
• Keep the bottle tightly closed and in its original carton to protect from light.
• Keep out of the reach and sight of children.
• Do not use the solution if it has changed color or become cloudy.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Careprost is a prescription medication and must be used under the direct supervision of a qualified healthcare professional. A thorough eye examination and patient history should be conducted by a physician to determine suitability for treatment. The patient must be informed of the potential benefits and risks, including the possibility of permanent changes. The user assumes all risks associated with the use of this product. Always follow the specific instructions provided by your prescribing doctor and the official product literature.

Reviews

• Clinical Study Data: Phase III clinical trials demonstrated that after 16 weeks of treatment, patients using bimatoprost 0.03% experienced a 25% increase in eyelash length, a 106% increase in overall eyelash darkness, and a 18% increase in fullness ( eyelash thickness) compared to vehicle-treated control groups. Patient satisfaction scores were significantly higher in the treatment group.
• Aesthetic Dermatologist, MD: “In my practice, Careprost remains the gold-standard, evidence-based treatment for eyelash hypotrichosis. The results are predictable and significant for compliant patients. My primary counseling points always involve managing expectations regarding the timeline for results and the discussion of potential permanent side effects like iris darkening, which is a crucial part of the informed consent process.”
• Patient Testimonial (Compiled): Many long-term users report high satisfaction with the aesthetic outcomes, noting that the regimen becomes a simple part of their nightly routine. Common feedback highlights the initial waiting period of 2 months before visible changes occur. Some users report mild, transient redness or itching upon initiation that typically subsides. A subset of users expresses concern over the cost and the commitment required to maintain results.